NYSEAMERICAN : SER
Serina Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 49.28M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 49.53M |
| Enterprise Value | 30.26M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 25.40M |
| Shares Outstanding | 25.40M |
| Shares Change (YoY) | +30.50% |
| Shares Change (QoQ) | +36.01% |
| Owned by Insiders (%) | 39.67% |
| Owned by Institutions (%) | 5.55% |
| Float | 11.15M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.63 |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.65 |
| Quick Ratio | 6.12 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -43.06 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -207.94% |
| Return on Assets (ROA) | -92.30% |
| Return on Invested Capital (ROIC) | -130.98% |
| Return on Capital Employed (ROCE) | -116.37% |
| Weighted Average Cost of Capital (WACC) | 5.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.50M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 18,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -58.81% |
| 50-Day Moving Average | 2.15 |
| 200-Day Moving Average | 2.09 |
| Relative Strength Index (RSI) | 52.33 |
| Average Volume (20 Days) | 49,402 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 43,870 |
| Short Previous Month | 119,360 |
| Short % of Shares Out | 0.17% |
| Short % of Float | 0.39% |
| Short Ratio (days to cover) | 0.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -14.07M |
| Operating Income | -25.66M |
| Pretax Income | -21.17M |
| Net Income | -23.93M |
| EBITDA | -25.59M |
| EBIT | -25.66M |
| Earnings Per Share (EPS) | -$1.93 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 23.02M |
| Total Debt | 3.75M |
| Net Cash | 19.27M |
| Net Cash Per Share | $0.76 |
| Equity (Book Value) | 18.73M |
| Book Value Per Share | 0.74 |
| Working Capital | 21.27M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -21.14M |
| Capital Expenditures | -66,000 |
| Depreciation & Amortization | 76,000 |
| Net Borrowing | 4.91M |
| Free Cash Flow | -21.20M |
| FCF Per Share | -$0.83 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -30.50% |
| Shareholder Yield | -30.50% |
| Earnings Yield | -99.23% |
| FCF Yield | -43.02% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.50 |
| Price Target Difference | 387.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.31 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |